BCKDK and non-small cell lung carcinoma: ABCB1, one of the most well‐characterized human efflux transporters, is predominantly expressed in the intestine, kidney, liver, and blood‐brain barrier.[60] Activation of the AKT signaling pathway contributes to ABCB1 expression and function in cisplatin‐resistant NSCLC cells.[61] In TNBC, DOX has been shown to regulate BCAA metabolism, implicating BCKDK as a DOX‐sensitive target,[47] although the exact mechanism remains unclear.